We delivered solid progress in the first quarter of 2021 and continued to advance our portfolio of life-changing medicines. Oncology grew 16% and New CVRM grew 15%. New medicines contributed over half of revenue and all regions delivered encouraging growth.
Pascal Soriot, Executive Director and Chief Executive Officer
Accelerating our strategic and financial development
AstraZeneca to acquire Alexion
We have
166
projects in our pipeline
Latest presentations
Q1 2021 results
Corporate Press Release